ArticleJournal of magnetic resonance imaging : JMRI2026
Prognostic Value of MRI-Based Left Ventricular Trabecular Complexity for Sudden Cardiac Death in Hypertrophic Cardiomyopathy.
Article in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial for "Prognostic Value of MRI-Based Left Ventricular Trabecular Complexity for Sudden Cardiac Death in Hypertrophic Cardiomyopathy".Journal of magnetic resonance imaging : JMRI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death (SCD). Early identification of high-risk patients is important for guiding preventive measures. PURPOSE: To validate left ventricular (LV) myocardial trabecular complexity using fractal dimension (FD) for SCD prediction in a larger cohort and investigate its relationship with sarcomere variants. STUDY TYPE: Prospective. POPULATION: 835 HCM patients (506 men; 50.7 ± 14.4 years). FIELD STRENGTH/SEQUENCE: Steady-state free precession (SSFP) cine sequence at 3 T. ASSESSMENT: Two cardiologists, blinded to clinical outcomes, independently analyzed assigned cardiac MRI cases. Biventricular function, late gadolinium enhancement, and LV FD were measured with fracAnalyse. The endpoint was SCD or aborted SCD. Sarcomere variants were classified by the American College of Medical Genetics and Genomics criteria, and their associations with FD were assessed. STATISTICAL TESTS: Cox regression assessed associations with SCD. Kaplan-Meier analysis and log-rank test were used to compare SCD incidence. Harrell's C-index assessed model discrimination. Welch's t-test compared FD between variant groups. Two-sided p < 0.05 indicated significance.
resultsGlobal FD (hazard ratio [HR] per 0.01 increase, 1.07, 95% CI: 1.01-1.15) and maximal apical FD (HR, 1.08, 95% CI: 1.02-1.14) independently predicted SCD after adjustment for European Society of Cardiology and American Heart Association risk predictors. High global FD (≥ 1.256) or maximal apical FD (≥ 1.352) improved model discrimination (C-index: 0.779-0.803, 0.77-0.791). MYBPC3 carriers had significantly higher maximal apical FD (1.35 ± 0.05 vs. 1.33 ± 0.07), maximal basal FD (1.35 ± 0.05 vs. 1.32 ± 0.06), and mean basal FD (1.28 ± 0.06 vs. 1.25 ± 0.07) than other sarcomere variant carriers. DATA
conclusionLV global and apical FDs provide independent and incremental prognostic value for predicting SCD. MYBPC3 variant carriers exhibited elevated FD values, linking trabecular complexity with genetic variants in HCM. EVIDENCE LEVEL: 2. TECHNICAL EFFICACY: Stage 3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.